Will new ‘bivalent booster’ head off a winter Covid wave?
The jab combines the original form of the Covid vaccine with a version tailored for Omicron
A new Covid vaccine designed to target both the original virus and the newer Omicron variant is set to be rolled out in the UK after being approved by the country’s medicines regulator in a world first.
Made by Moderna, the bivalent vaccine is known as “Spikevax bivalent Original/Omicron” and combines the original form of the Covid vaccine with a version tailored for Omicron variant BA.1, “the strain that fuelled a wave of Covid in the UK last winter”, said The Guardian’s science correspondent Nicola Davis.
But while the UK is leading the way in approving the new jab for adult booster doses, some experts have suggested the vaccine “may not offer huge gains in the fight” to prevent another wave of winter infections, Davis reported.
Subscribe to The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.
Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
How does the bivalent booster work?
In each dose, “half of the vaccine (25 micrograms) targets the original virus strain from 2020 and the other half (25 micrograms) targets Omicron”, said the Medicines and Healthcare products Regulatory Agency (MHRA).
Coronavirus is “continually evolving in order to evade the immunity provided by vaccines”, said Professor Munir Pirmohamed, chair of the Commission on Human Medicines. “This novel bivalent vaccine represents the next step in the development of vaccines to combat the virus, with its ability to lead to a broader immune response than the original vaccine.”
Who will get the new booster and when?
Britain’s autumn Covid vaccination campaign is due to begin in September, with 26m people to be invited to get a fresh dose, including “the over-50s, healthcare workers and the vulnerable”, The Telegraph’s science correspondent Joe Pinkstone reported.
The Joint Committee for Vaccinations and Immunisations (JCVI) “has said that Moderna’s Omicron vaccine will be the default option” throughout the boost campaign, Pinkstone added. But “should there be supply issues then older versions will be used, with the most vulnerable prioritised for the new jab”.
Will it head off a winter wave of Covid?
The decision to approve the new jab is based on a clinical trial that “showed that a booster with the bivalent Moderna vaccine triggers a strong immune response against both Omicron (BA.1) and the original 2020 strain”, said the Medicines and Healthcare products Regulatory Agency. “In an exploratory analysis the bivalent vaccine was also found to generate a good immune response against the Omicron sub-variants BA.4 and BA.5.”
According to US pharma giant Moderna, trial participants who were given the booster had antibody levels against these sub-variants that were 1.69 times higher than those given the original booster.
BA.4 and BA.5 “fuelled the most recent Covid wave in the UK, and have caused infections, breakthrough reinfections, deaths and disruption around the world”, said The Guardian’s Davis.
But some experts fear that the new vaccine may offer only marginal gains in the push to prevent further suffering.
“This is a really difficult juncture for all policymakers in terms of vaccine booster procurement and booster programmes,” Danny Altmann, a professor of immunology at Imperial College London, told the paper.
“We lack the certainties we had in early 2020 of which way to go with the vaccines, not least, how to keep up with evolution of the variants. BA.5 is highly immune evasive so that even boosted people have highly impaired protection. Even exposure to the original Omicron sequence – as used in this, new, bivalent vaccine booster – only gives a rather marginal advantage to the antibody response.”
But “any booster programme is better than nothing, and this bivalent booster almost certainly an improvement over the first-generation vaccines”, Altmann added.
“My view is that this approach offers a marginal improvement in our battle against BA.5, but actually, we still need to think harder about this and look more broadly at the diverse vaccine candidates. In the meantime, get boosted.”
Sign up for Today's Best Articles in your inbox
A free daily email with the biggest news stories of the day – and the best features from TheWeek.com
-
Today's political cartoons - November 2, 2024
Cartoons Saturday's cartoons - anti-fascism, early voter turnout, and more
By The Week US Published
-
Geoff Capes obituary: shot-putter who became the World’s Strongest Man
In the Spotlight The 'mighty figure' was a two-time Commonwealth Champion and world-record holder
By The Week UK Published
-
Israel attacks Iran: a 'limited' retaliation
Talking Point Iran's humiliated leaders must decide how to respond to Netanyahu's measured strike
By The Week UK Published
-
What went wrong at CVS?
Today's Big Question Pharmacy chains are in crisis
By Joel Mathis, The Week US Published
-
Long Covid: study shows damage to brain's 'control centre'
The Explainer Research could help scientists understand long-term effects of Covid-19 as well as conditions such as MS and dementia
By The Week UK Published
-
Israel, UN agree to Gaza pauses for polio vaccinations
Speed Read Gaza's first case of polio in 25 years was confirmed last week in a 10-month-old boy who is now partially paralyzed
By Rafi Schwartz, The Week US Published
-
FDA OKs new Covid vaccine, available soon
Speed read The CDC recommends the new booster to combat the widely-circulating KP.2 strain
By Peter Weber, The Week US Published
-
Mpox: how dangerous is new health emergency?
Today's Big Question Spread of potentially deadly sub-variant more like early days of HIV than Covid, say scientists
By The Week UK Published
-
WHO declares mpox a global health emergency
Speed Read An outbreak of the viral disease formerly known as monkeypox continues to spread in Africa
By Rafi Schwartz, The Week US Published
-
What is POTS and why is it more common now?
The explainer The condition affecting young women
By Devika Rao, The Week US Published
-
Brexit, Matt Hancock and black swans: five takeaways from Covid inquiry report
The Explainer UK was 'unprepared' for pandemic and government 'failed' citizens with flawed response, says damning report
By Harriet Marsden, The Week UK Published